REDWOOD CITY, Calif.,
March 8, 2021 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company, today announced that it will release fourth quarter
financial results after market close on Monday, March 15, 2021. AcelRx management will
host a live webcast and conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on March 15, 2021 to discuss the financial results
and provide an update on the company's business.
The webcast is accessible by visiting the Investors page of the
company's website at www.acelrx.com and clicking on the webcast
link on the Investors home page. The webcast will be accompanied by
a slide presentation. A webcast replay will be available on
the AcelRx website for 90 days following the call by visiting the
Investor page of the company's website at www.acelrx.com.
Investors who wish to participate in the conference call may do
so by dialing (866) 361-2335 for domestic callers, (855) 669-9657
for Canadian callers, or (412) 902-4204 for international
callers.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's proprietary,
non-invasive sublingual formulation technology delivers sufentanil
with consistent pharmacokinetic profiles. The Company has one
approved product in the U.S., DSUVIA®(sufentanil sublingual tablet,
30 mcg), known as DZUVEO™ in Europe, indicated for the management of acute
pain severe enough to require an opioid analgesic for adult
patients in certified medically supervised healthcare settings, and
one product candidate, Zalviso®(sufentanil sublingual tablet
system, SST system, 15 mcg), being developed as an innovatively
designed patient-controlled analgesia (PCA) system for reduction of
moderate-to-severe acute pain in medically supervised settings.
DZUVEO and Zalviso are both approved products in Europe. Zalviso is an investigational drug and
not approved in the U.S. For additional information about AcelRx,
please visit www.acelrx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/acelrx-to-host-fourth-quarter-and-full-year-2020-financial-results-call-and-webcast-on-march-15-2021-301242642.html
SOURCE AcelRx Pharmaceuticals, Inc.